Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $475.49, marking a -1.41% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 3.46%.

In its first quarter 2025 investor letter, GreensKeeper Asset Management emphasized stocks such as Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ ...

Will these developments be enough to sustain the rally? Let's discuss whether Vertex Pharmaceuticals stock is a buy now. The past year has been transformative for Vertex, marked by the launch of ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective increased by Bank of America from $555.00 to $567.00 in a research note issued on Monday,Benzinga reports.

Analysts' ratings for Vertex Pharmaceuticals VRTX over the last quarter vary from bullish to bearish, as provided by 17 analysts. The table below summarizes their recent ratings, showcasing the ...

With a market cap of $122.6 billion, Vertex Pharmaceuticals Incorporated (VRTX) operates as a global biotechnology company ...